Amgen Inc. (AMGN)
| Market Cap | 166.71B |
| Revenue (ttm) | 29.53B |
| Net Income (ttm) | 3.76B |
| Shares Out | 536.43M |
| EPS (ttm) | 7.01 |
| PE Ratio | 44.33 |
| Forward PE | 14.90 |
| Dividend | $9.00 (2.90%) |
| Ex-Dividend Date | May 16, 2024 |
| Volume | 1,542,113 |
| Open | 310.25 |
| Previous Close | 311.01 |
| Day's Range | 307.60 - 312.43 |
| 52-Week Range | 218.44 - 329.72 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 306.68 (-1.32%) |
| Earnings Date | Aug 1, 2024 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N... [Read more]
Financial Performance
In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $306.68, which is a decrease of -1.32% from the latest price.
News
Weighing the Future of Weight Loss Drugs
How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
PLTR, AMGN, LMT: Must Watch Stocks
Palantir (PLTR) shares are trading between the $20 to $25 range. Amgen (AMGN) is coming out of the GLP-1 Phase 3 trial with a once a month delivery versus once a week.
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
BLINCYTO ® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Versus Chemotherapy Alone First and Only Bispecific T-cell Engager (BiTE ®) ...
A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL
The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to signif...
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA ® and Progress in Addressing Sjögren's Disease THOUSAND OAKS, Calif. , June 12, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today anno...
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 9:20 a.m.
Amgen's drug meets main goal in late-stage study for rare disease
Amgen said on Wednesday its drug to treat patients with an immune system-related condition has met the main goal of a late-stage study.
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
Data Show a Statistically Significant 87% Reduction in IgG4-RD Flares, With Primary and All Key Secondary Endpoints Met First Randomized, Placebo-Controlled Trial to Demonstrate Benefit in IgG4-RD THO...
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , June 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m.
Should you buy Amgen's stock above $300?
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts project significant growth in this sector, with Amgen among key players lik...
Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval
Pharmaceutical regulators approved Amgen's AMGN, -1.85% Bkemv, a biosimilar to rare-disease treatment Soliris.
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris.
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS® (sotorasib) Plus Vectibix® (panitumuma...
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif. , May 19, 2024 /PRNews...
Amgen gets FDA approval for small-cell lung-cancer treatment
Amgen AMGN, -0.65% on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall S...
FDA approves Amgen's treatment for most deadly form of lung cancer
The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.
US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports
The U.S. Food and Drug Administration has granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despit...
The Best Dividend Stocks For A Dovish Fed
Remember when the Federal Reserve stopped printing money for a few months? It didn't go well.
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m.
Trade Tracker: Joe Terranova buys Amgen and Merck
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest buys
Is Eli Lilly Stock A Better Pick Over Amgen?
Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the luc...
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.